Curemark: Funding, Investors & Team (Sep 2026)
Curemark is a biopharmaceutical company that focuses on the development of novel therapies to treat serious diseases for which there are limited treatment options for patients in need. It blends a unique business model with an expert team to bring promising medical technologies to patients. Their pipeline includes two Phase III clinical-stage programs for Autism and ADHD as well as three preclinical programs directed at Parkinson’s Disease, Schizophrenia, and Addiction. All of their product candidates address severe neurologic diseases that are currently believed to be underserved by available approved therapies and represent large potential commercial market opportunities. They believe that their product candidates offer innovative therapeutic approaches and may have the potential to provide significant advantages relative to current therapies.
Curemark has raised $1.5M across 1 funding round on record, the most recent an undisclosed round of $1.5M announced in Apr 2021.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Curemark Company Profile and Key Stats
Latest funding round on record: Apr 2021.
Curemark Funding Rounds
Curemark Founders and Leadership Team
No contact details are on record for this team yet.
Curemark Funding Compared to Other Biotechnology Startups
Curemark's latest round of $1.5M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Curemark in Biotechnology and Rye
Companies Similar to Curemark
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Curemark Funding FAQs
What does Curemark do?
Curemark is a biopharmaceutical company that focuses on the development of novel therapies to treat serious diseases for which there are limited treatment options for patients in need. It blends a unique business model with an expert team to bring promising medical technologies to patients. Their pipeline includes two Phase III clinical-stage programs for Autism and ADHD as well as three preclinical programs directed at Parkinson’s Disease, Schizophrenia, and Addiction. All of their product candidates address severe neurologic diseases that are currently believed to be underserved by available approved therapies and represent large potential commercial market opportunities. They believe that their product candidates offer innovative therapeutic approaches and may have the potential to provide significant advantages relative to current therapies.
How much funding has Curemark raised?
Curemark has raised $1.5M across 1 round on record. The most recent is an undisclosed round of $1.5M announced in Apr 2021.
When did Curemark last raise funding?
Curemark's most recent funding round on record is an undisclosed round of $1.5M, announced in Apr 2021.
Who is the CEO of Curemark?
Joan Fallon is listed as CEO at Curemark.
Where is Curemark headquartered?
Curemark is based in Rye, New York, United States.
How many employees does Curemark have?
Curemark is in the 11-50 employee band.
How does Curemark's funding compare to other Biotechnology startups?
Curemark's latest round of $1.5M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Curemark Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Curemark is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.